CBI and PharmaVoice Announce Recipients of the Strategic Patient Adherence Awards

WOBURN, Mass., April 30 /PRNewswire/ -- AstraZeneca, Eli Lilly and Rx Canada received top honors at the 2008 Strategic Patient Adherence (SPA) Awards. Rx Canada and their client (AstraZeneca Canada), the first international award winners, received awards for the Best Branded Compliance Program. The Health Inform(R) Programs for Crestor, Symbicort and Nexium medications were lauded for measurement of each program's effectiveness. "I really liked the way in which they measured and published their results," said Robert Nauman, BioPharma Advisors and a judge for the SPA awards. Rx Canada and their client (Eli Lilly Canada) received an innovation award for the Evista Inner Strength Program which ensured that pharmacists followed up with patients 2 weeks after their first intervention. Finally, AstraZeneca received an innovation award for the SERV(TM) Program, which is a platform that allows AZ brands to leverage the sales force to provide messages, tools and programs to physicians toward enhancing medication adherence in their patients.

The prestigious Strategic Patient Adherence (SPA) Awards co-sponsored by CBI and PharmaVoice were presented at the 7th Annual Forum on Patient Compliance, Adherence and Persistency held April 24th in Philadelphia, PA. These awards provided a forum that pays tribute to outstanding programs in the areas of patient compliance/adherence and persistency.

Awards were given to pharmaceutical organizations that met pre-defined criteria in 5 categories: Innovation, Quality, Measurement, Satisfaction, Health Outcomes & ROI. Programs that have been deemed exceptional in their compliance initiatives usually score above 60 points on the judging scale. Each entry was reviewed by this year's judging panel made up of Grant Corbett, Founder of Behavior Change Solutions, Inc., Robert Nauman, Principal at BioPharma Advisors, John Heilman, Senior Commercial Analytics Manager, New Practice and Corporate Analytics, AstraZeneca, Glenn Gary, Senior Marketing Manager, Amgen, and Dorothy L. Smith, Pharm.D, President of Consumer Health Information. Both John and Gary are previous award winners of the SPA award.

"The SPA awards were a success because these programs incorporate the best practices that occur in the industry today. This year's winners proved the value and validity against some nationally recognized criteria for patient compliance, adherence and persistency programs," said Grant Corbett, Principal, Behavior Change Solutions and a judge for the SPA awards.

For information about next year's awards please contact Jackie Harrington at 781-939-2405 or Email: [email protected]

About CBI Research, Inc. (http://www.cbinet.com)

Founded in 1994 in Massachusetts, CBI Research, Inc. is dedicated to developing market-driven, unbiased conferences in pharmaceuticals\biotech, medical devices, risk and insurance and managed care markets. CBI Research, Inc. offers conferences and summits that serve senior executives and government officials by providing a unique platform for highly focused content and presentation. As a delegate, speaker or sponsor, you receive timely information on the latest investment opportunities, business strategies, domestic and international regulatory issues, operations and applied technologies. Our events provide you with concrete, real life examples that you can begin to apply at your organization immediately for significant impact on costs and revenue. Plus, there are extensive opportunities for networking and discussion with senior policy and decision makers. CBI Research, Inc. was acquired by Advanstar Communications, Inc. in February of 2008.

SOURCE CBI Research, Inc.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.